- Home
- CANF vs AQMS Comparison
CANF vs AQMS Comparison
Compare CANF & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- AQMS
- Stock Information
- Founded
- CANF 1994
- AQMS 2014
- Country
- CANF Israel
- AQMS United States
- Employees
- CANF N/A
- AQMS N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- AQMS Metal Fabrications
- Sector
- CANF Health Care
- AQMS Industrials
- Exchange
- CANF Nasdaq
- AQMS Nasdaq
- Market Cap
- CANF 9.6M
- AQMS 10.3M
- IPO Year
- CANF N/A
- AQMS 2015
- Fundamental
- Price
- CANF $0.50
- AQMS $9.80
- Analyst Decision
- CANF Strong Buy
- AQMS Buy
- Analyst Count
- CANF 2
- AQMS 1
- Target Price
- CANF $14.50
- AQMS $30.00
- AVG Volume (30 Days)
- CANF 280.9K
- AQMS 5.2M
- Earning Date
- CANF 11-27-2025
- AQMS 11-13-2025
- Dividend Yield
- CANF N/A
- AQMS N/A
- EPS Growth
- CANF N/A
- AQMS N/A
- EPS
- CANF N/A
- AQMS N/A
- Revenue
- CANF $560,000.00
- AQMS N/A
- Revenue This Year
- CANF $461.72
- AQMS N/A
- Revenue Next Year
- CANF N/A
- AQMS $550.00
- P/E Ratio
- CANF N/A
- AQMS N/A
- Revenue Growth
- CANF N/A
- AQMS N/A
- 52 Week Low
- CANF $0.47
- AQMS $3.37
- 52 Week High
- CANF $3.02
- AQMS $39.40
- Technical
- Relative Strength Index (RSI)
- CANF 31.15
- AQMS 50.70
- Support Level
- CANF $0.49
- AQMS $11.56
- Resistance Level
- CANF $0.55
- AQMS $39.37
- Average True Range (ATR)
- CANF 0.03
- AQMS 4.64
- MACD
- CANF -0.00
- AQMS -0.03
- Stochastic Oscillator
- CANF 13.94
- AQMS 13.29
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.